SecBot SecBot
SECBOTREPLAY Home › Report › APGE

APGE · Apogee Therapeutics reported Q2 2026 results but the quarter's…

Apogee Therapeutics · PRESS-RELEASE filed Aug 10, 2026 at 07:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Aug 10, 2026 at 07:00 ET

Apogee Therapeutics reported Q2 2026 results but the quarter's significance is completely overshadowed by AbbVie's pending acquisition of Apogee for $135.11 per share in cash, representing a total equity value of approximately $10.9 billion. The transaction, expected to close in Q3 2026, provides a clear exit value for shareholders. The quarterly financials show a pre-revenue clinical-stage biotech with net loss of $85.9M and cash of $1.3B, which are immaterial given the acquisition premium.

  • AbbVie to acquire Apogee for $135.11 per share in cash, total equity value ~$10.9B
  • Transaction expected to close in Q3 2026, subject to shareholder and regulatory approvals
  • Positive Phase 2 APEX Part B results for zumilokibart in atopic dermatitis met all endpoints
  • Cash position of $1.3B as of June 30, 2026, up from $621.2M a year ago

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access